Recurrence-Free Survival in High-Risk Stage III Melanoma With Pembrolizumab Confirmed by Long Term Follow-up
source: pixabay.com

Recurrence-Free Survival in High-Risk Stage III Melanoma With Pembrolizumab Confirmed by Long Term Follow-up

  According to a recent report in the Journal of Clinical Oncology, over one thousand patients with high-risk stage III melanoma were included in the Keynote-054 clinical trial (NCT02362594). The…

Continue Reading Recurrence-Free Survival in High-Risk Stage III Melanoma With Pembrolizumab Confirmed by Long Term Follow-up
First Patient Dosed in Phase 2 Trial to Evaluate AU-011 for Choroidal Melanoma
cocoparisienne / Pixabay

First Patient Dosed in Phase 2 Trial to Evaluate AU-011 for Choroidal Melanoma

  Recently, clinical-stage biopharmaceutical company Aura Biosciences announced a Phase 2 clinical trial to determine the safety, efficacy, and tolerability of AU-011 for patients with choroidal melanoma. Currently, Aura Biosciences…

Continue Reading First Patient Dosed in Phase 2 Trial to Evaluate AU-011 for Choroidal Melanoma
MD Anderson Physicians Use a Diagnostic Method Called Sentinel Lymph Node Biopsy To Determine Spread of Cancer
marionbrun / Pixabay

MD Anderson Physicians Use a Diagnostic Method Called Sentinel Lymph Node Biopsy To Determine Spread of Cancer

Although some ultrasound and/or CT scan studies may show that patients’ lymph nodes (glands) are free of disease, upon further examination using sentinel lymph node biopsies,(SLNB) the doctors at MD…

Continue Reading MD Anderson Physicians Use a Diagnostic Method Called Sentinel Lymph Node Biopsy To Determine Spread of Cancer
Researches Are Developing a Way to Predict Who Will Respond to Checkpoint Inhibitors for Melanoma
Pexels / Pixabay

Researches Are Developing a Way to Predict Who Will Respond to Checkpoint Inhibitors for Melanoma

A recent study, carried out by researchers from the National Cancer Institute (part of the NIH) and several other universities, outlines a potential new method of predicting whether immune checkpoint…

Continue Reading Researches Are Developing a Way to Predict Who Will Respond to Checkpoint Inhibitors for Melanoma
$2.6 million has Been Granted to Researchers Working on Reducing the Side-Effects of Checkpoint Inhibitor Immunotherapies For Cancer Patients
Source: Pixabay

$2.6 million has Been Granted to Researchers Working on Reducing the Side-Effects of Checkpoint Inhibitor Immunotherapies For Cancer Patients

The Melanoma Research Alliance (MRA) and The American Cancer Society (ACS) have announced the first recipients of their new research grants, reports PRNewswire. The grants have been set up as…

Continue Reading $2.6 million has Been Granted to Researchers Working on Reducing the Side-Effects of Checkpoint Inhibitor Immunotherapies For Cancer Patients